Effect of carnitine on patients with heart failure: an evidence-based case report

Yosua Y Kristian1, Wiji Lestari1

1. Department of Nutrition, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Abstract

Background: Heart disease is one of the leading causes of death in Indonesia. Nutritional management plays an important role in overcoming heart disease, both as prevention and treatment. Carnitine plays a role in fat metabolism and can reduce the formation of thrombosis, resulting in improved heart function and quality of life of patients.

Objectives: This study is aimed to identify the effect of carnitine in patients with heart failure.

Methods: Existing research findings and articles are selected based on inclusion and exclusion criteria in three databases, namely PubMed, Cochrane and Wiley. The outcome were functional capacity and heart function.

Results: One meta-analysis that address with the clinical questions was obtained, and based on that article, giving carnitine to patients with heart failure has effects on increasing functional capacity, heart function, BNP serum and NT-proBNP levels. However, no effects found on mortality. Furthermore, no significant side effects on carnitine was found.

Conclusions: Carnitine supplementation at a dose of 1 up to 6 g/day has a positive impact on functional capacity, heart function, BNP serum and NT-proBNP levels in patients with heart failure, alongside with minimal side effects.

Keywords: carnitine, heart failure, outcome

Clinical scenario

Mr. S, age 50, was admitted to the emergency room with the chief complaint of shortness of breath for the last 3 days, which would arise suddenly and become worse when in a sleeping position. History of diabetes was denied, however he had a history of high blood pressure for the past one year and was not taking medications regularly. Physical examination revealed cardiomegaly, normal heart sounds, no murmurs or gallops. Laboratory results: Hb 16 g/dL, leukocytes 6500/mm3, platelets 230,000/uL, LDL 243 mg/dL, triglycerides 267 mg/dL, uric acid 10 mg/dL, troponin I 0.29 ng/mL, BNP 312 pg/mL. Electrocardiography test showed an enlarged left ventricle. The patient's body weight was 65.7 kg, with a height of 160 cm, and a body mass index of 25.6 kg/m2. The patient was hospitalized and received treatment from internists and clinical nutrition specialists. Patient was diagnosed with obesity grade 1,1 heart failure class 4 according to the New York Heart Association (NYHA), dyslipidemia, and hyperuricemia. Patient was given oral carnitine supplementation when discharged from the hospital at a dose of 1.5 g/day for 3 months.
of carnitine given orally in accordance with the needs of 3 g/day or more on mortality rate in patients with acute myocardial infarction did not show any significant impact.\textsuperscript{10}

This evidence-based case report will discuss specifically about the effects of carnitine on patients with heart failure.

**Clinical questions**

P: Adult patients with heart failure
I: Carnitine
C: Without carnitine
O: Functional capacity and heart function

Clinical question: What is the effect of carnitine as a nutritional management on functional capacity and heart function in patients with heart failure?

**Methods**

Article Search Strategy

Existing research articles were generated from PubMed, Cochrane Library, and Wiley Online on December 12, 2019. Searching terminology is described in Table 1.

Article Selection Strategy

Eligibility Criteria

Screening is based on MesH Term, an assessment of conformity with PICO, and with inclusion and exclusion criteria. The inclusion criteria were 1. Study subjects were adult patients (aged ≥18 years old), 2. Subjects diagnosed with heart failure with various stages 3. Clinical trials or meta-analysis with carnitine treatment 4. Journals published in the last 5 years 5. Tests clinically carried out in humans. Meanwhile, the exclusion criteria were 1. Journal is not written in English and 2. full text is not available.

Method of critical appraisal

All authors did the critical appraisal by using the method according to the Center of Evidence Based Medicine (\url{www.cebm.net}) for intervention studies that has been modified in Indonesian language.

**Findings**
Based on the results of the search from the database, and by assessing the inclusion and exclusion criteria, an article that is eligible to be included as a reference for critical review is used (Figure 1). Selected articles are meta-analysis of clinical trials, with a total number of 1625 patients. The length of follow-up of the subject in the articles is from 7 days to 3 years. Carnitine given to patients with a dose of 1 to 6 g/day.

The articles obtained have a level of evidence 1, which is a meta-analysis of 17 clinical trials. Findings from articles used in this work illustrate that carnitine administration has a positive impact on functional capacity and heart function. The validity of the criteria can be seen in table 3. The relevance of the criteria can be seen in table 4.

There were no differences of mortality rate in patients with heart failure (p= 0.08) and carnitine side effects (p=0.83), there was an increase in functional capacity marked by a decrease in NYHA class (p<0.01), decrease in BNP serum markers (p=0.01) and NT-proBNP (p<0.01), as well as increased cardiac function (p<0.01).

Discussion

Song X et al. conducted a meta-analysis study for the effects of carnitine supplementation on patients with heart failure with a search time limit until September 30, 2016. The study looked for randomized controlled literature from various databases, abstracts of scientific meetings, as well as manually from unpublished articles and studies. Based on the search, 17 appropriate journals were found, with a total of 1625 research subjects. Patients’ age ranged between 43 and 78 years. Carnitine dosage given ranged from 1 to 6 g/day, and administered from 7 days to 3 years. Patients receiving carnitine were classified as NYHA class II-IV, with a LVEF of 27% to 52% before the intervention.

Outcomes from this study showed that carnitine had a positive impact on the functional capacity, which is characterized by a decrease in NYHA class. The literature that has the greatest weight in the meta-analysis was the research conducted by Jing ZC et al. The study gave carnitine of 1 g intravenously, twice a day for seven days. The effectiveness of carnitine reached 60.7% compared to the control group of 44.7% (P = 0.012). The 6-minute walk test did not show significant difference between control and intervention (P = 0.14). The study from Song X et al. also showed that carnitine had positive effect on serum-BNP (P = 0.01) and NT-proBNP (P = 0.0003). Both BNP and NT-proBNP can act as prognostic factors in patients with heart failure or in patients with asymptomatic left ventricular dysfunction.

The heart function also showed significant improvement. The heart functions assessed were LVEF (P <0.00001), SV (P <0.00001), CO (P <0.00001), E / A ratio (P = 0.0003), LVESD (P = 0.002), LVEDD (P <0.0001), and LVESV (P = 0.01). The antioxidant effect of carnitine can prevent the formation of superoxide in heart muscle and excessive inflammation, which results in changes in heart structure.

There was no impact on the mortality of patients with heart failure, both in intention to treat analysis and per protocol. From a total of ten literature, six literatures showed no side effects of carnitine administration in patients with heart failure, while four studies report side effects such as dry mouth and gastrointestinal disorders. One literature reported that there was skin rash as a side effect, but it did occur in both treatments, both the control group and the intervention group.

Based on the article in this evidence-based case report, it can be concluded that administration of carnitine can improve the quality of life of patients with heart failure, improve heart function and serum levels of BNP and NT-proBNP, with minimal side effects. Carnitine can be given orally by using carnitine supplements, and using food sources. Examples of food sources of carnitine are beef, with carnitine of 2320 mg/kg dry weight, duck meat with carnitine 732 mg/kg dry weight, skim milk with carnitine 400 mg/kg dry weight, condensed milk 396 mg/kg dry weight, and yogurt 142-139 mg/kg dry weight.

Recommendation:
Patients with heart failure can be given carnitine at least 1 g/day to 6 g/day. In administration of carnitine at a dose of 1 g, it can be given for 1 year, a dose of 1.5 g carnitine with a duration of 3 months, while a dose of 3 g and 6 g can be given for 7 days.
Conclusion

Patients included in defined clinical scenario can be given carnitine up to 6 g/day, in the form of supplementation or derived from food sources such as milk, milk products, or meat. Giving carnitine can improve the quality of life of patients, heart function, reduce BNP serum and NT-proBNP levels, with minimal side effects. Giving carnitine has no impact on the mortality of patients with heart failure.

**Figure 1.** PRISMA flow chart
Table 1. Terminology

| Database      | Terminology                                                                 | Hits | Eligible |
|---------------|-----------------------------------------------------------------------------|------|----------|
| PubMed        | (((carnitine[MeSH Terms]) OR carnitine[Title])) AND ((heart failure[MeSH Terms]) OR heart failure[Title]) | 116  | 1        |
|               | ID Search                                                                  |      |          |
|               | #1 "heart failure"                                                          | 28578|          |
|               | #2 carnitine                                                               | 1705 |          |
| Cochrane      | #3 MeSH descriptor: [Carnitine] explode all trees                           | 606  |          |
| Library       | #4 MeSH descriptor: [Heart Failure] explode all trees                       | 8482 |          |
|               | #5 #2 OR #3                                                                 | 1719 |          |
|               | #6 #4 AND #6                                                                | 18   |          |
| Wiley Online  | “carnitine” AND “heart failure” in Keywords                                | 6    | 0        |

Table 2. Study characteristics

| Article                      | Study design | Characteristics of the population | Number of subjects | Age group (years) | Intervention | Control | Outcome                                           | Follow up Period |
|------------------------------|--------------|----------------------------------|--------------------|-------------------|--------------|---------|---------------------------------------------------|------------------|
| Song X, et al (2017)         | Meta analysis| Patients with heart failure      | 1625               | 43-78             | Carnitine    | Without carnitine | Functional capacity, heart function, BNP and NT-proBNP level, side effects | 7 days up to 3 years |

Table 3. Validity criteria

| Validity | Relevance | Artikel | Common point | Follow up | Blind fashion | Sub-group analysis | Outcome | Precise | Apply | Important | Result | Level of Evidence |
|----------|-----------|---------|--------------|-----------|---------------|-------------------|---------|---------|-------|-----------|--------|-------------------|
|          |           | Song X, et al (2017) | + | + | -* | + | + | + | + | A | 1 |

* Only 3 journals stated that there was blinding in patients and study members

Table 4. Relevance criteria

| Article                      | Similarity Population | Similarity determinant/indicators | Similarity Outcome |
|------------------------------|-----------------------|-----------------------------------|-------------------|
| Song X, et al (2017)         | +                     | +                                 | +                 |
**Conflict of interest**
The authors declare no conflict of interest regarding this study.

**Open Access**
This article is distributed under the terms of the Creative Commons Attribution 4.0 International Licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**
1. World Health Organization. Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; 2000. Available from: https://apps.who.int/iris/handle/10665/206936.
2. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol* 2014;63:1123-33.
3. Reyes EB, Ha JW, Firdaus I, Ghazi AM, Phrommintikul A, Sim D, et al. Heart failure across Asia: Same healthcare burden but differences in organization of care. *Int J Cardiol* 2016;223:163-7.
4. Wang ZY, Liu YY, Liu GH, Lu HB, Mao CY. L-Carnitine and heart disease. *Life Sci* 2018;194:88-97.
5. Borum PR. Carnitine in parenteral nutrition. *Gastroenterology* 2009;137:S129-34.
6. Lapillonne A, Fidler Mis N, Goulet O, van den Akker CHP, Wu J, Koletzko B, et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Lipids. *Clin Nutr* 2018;37:2324-36.
7. Kinuagasa Y, Hirai M, Yanagihara K, Haruki N, Matsubara K, Kato M, et al. Carnitine Paradox in Patients With Heart Failure. *Journal of Cardiac Failure* 2017;23.
8. Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 2013;128:e240-327.
9. Jing Z-C, Wu B-X, Peng J-Q, Li X-L, Pan L, Zhao S-P, et al. Effect of intravenous l-carnitine in Chinese patients with chronic heart failure. *European Heart Journal Supplements* 2016;18:A27-A36.
10. Shang R, Sun Z, Li H. Effect dosing of L-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis. *BMC Cardiovascular Disorders* 2014;14:88.
11. Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. *Biomed Res Int* 2017;2017:6274854.
12. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). *Circulation* 2003;107:1278-83.